New compounds inhibit cervical cancer

Japanese researchers recently reported that they have developed a compound that inhibits cervical cancer, which has been confirmed in animal experiments, and plans to conduct clinical trials this year.
hpV is the main cause of cervical cancer. Researchers at Kyoto University and other institutions in Japan, in a paper published recently in the American academic journal
, say they have developed a compound called FIT-039 that inhibits the proliferation of viruses in experiments using endocrine cells in patients with cervical cancer.
team conducted animal experiments, transplanting human cervical cancer cells into laboratory mice and feeding them the compound, and found that it also inhibited the proliferation of cancer cells in laboratory mice. After 3 weeks, the rate of cancer cell proliferation in the mice fed the drug was reduced by 30% compared to the control group, and no side effects were found.
researchers believe the compound may be a new option for preventing cervical cancer, and they will identify its effects on reproductive function in the future, between planning clinical trials in early cervical cancer patients in 2018. (Source: Xinhua News Agency, Huayi)